While some forms of hair loss are irreversible, others can be improved. In our essential guide, we've teamed up with experts ...

UCLA genetic scientists are reawakening hibernating follicles. A UCLA-discovered molecule, PP405, may finally offer real hope ...

Alopecia is an autoimmune disorder that causes non-scarring hair loss on the scalp and body that is experienced by almost 2% ...

On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose ...

Crystal Aguh, MD, FAAD, Johns Hopkins School of Medicine faculty, highlights the critical need for comprehensive education on hair loss across diverse hair types, stressing the importance of ...

Hair loss is such a common experience that many people go through, but it can seem like it hits us out of nowhere. There are ...

Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia ...

Alopecia is the general medical term for hair loss, which can come in different forms and severities. Hair loss is a common ...

STRATA Skin Sciences (SSKN) announces the results of a newly published study in Japan that further validates the technological advantages of ...

It’s time that insurance recognizes wigs as necessary medical expenses for those suffering from conditions like alopecia, ...

The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8 mg is efficacious and tolerable.